Protalix Biotherapeutics Inc Total Liabilities
Protalix Biotherapeutics Inc total liabilities. Based on the latest financial reports, Protalix Biotherapeutics Inc (PLX) has total liabilities worth $34.12 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check PLX cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Protalix Biotherapeutics Inc (1996–2025)
Total liabilities of Protalix Biotherapeutics Inc from 1996 to 2025. This chart illustrates how Protalix Biotherapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore PLX strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Protalix Biotherapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Protalix Biotherapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Plotech Co Ltd
TW:6141
|
Taiwan | NT$4.72 Billion |
|
E-Life Mall Corp
TW:6281
|
Taiwan | NT$6.29 Billion |
|
Angel Oak Mortgage Inc
NYSE:AOMR
|
USA | $2.55 Billion |
|
Smec Co.Ltd
KQ:099440
|
Korea | ₩217.41 Billion |
|
Holmes Place International Ltd
TA:HLMS
|
Israel | ILA1.34 Billion |
|
Formuepleje Limittellus
CO:FPILIM
|
Denmark | Dkr2.00K |
|
Chiang Mai Ram Medical Business Public Company Limited
BK:CMR
|
Thailand | ฿3.20 Billion |
|
Emilia Devel
TA:EMDV
|
Israel | ILA1.34 Billion |
Liability Composition Analysis (1996–2025)
This chart breaks down Protalix Biotherapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see PLX asset base.
Liquidity & Leverage Metrics
Protalix Biotherapeutics Inc Total Liabilities Ratios Explained
Protalix Biotherapeutics Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.51 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.55 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.71 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.41 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Protalix Biotherapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Protalix Biotherapeutics Inc (1996–2025)
The table below shows the annual total liabilities of Protalix Biotherapeutics Inc from 1996 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $34.12 Million | +12.94% |
| 2024-12-31 | $30.21 Million | -40.62% |
| 2023-12-31 | $50.87 Million | -23.43% |
| 2022-12-31 | $66.43 Million | -16.65% |
| 2021-12-31 | $79.70 Million | -16.08% |
| 2020-12-31 | $94.97 Million | -17.93% |
| 2019-12-31 | $115.71 Million | +1.49% |
| 2018-12-31 | $114.01 Million | +10.15% |
| 2017-12-31 | $103.51 Million | +12.26% |
| 2016-12-31 | $92.20 Million | +6.74% |
| 2015-12-31 | $86.38 Million | -35.57% |
| 2014-12-31 | $134.07 Million | -4.43% |
| 2013-12-31 | $140.28 Million | +70.90% |
| 2012-12-31 | $82.08 Million | +5.40% |
| 2011-12-31 | $77.88 Million | +2.41% |
| 2010-12-31 | $76.05 Million | -8.14% |
| 2009-12-31 | $82.79 Million | +1180.75% |
| 2008-12-31 | $6.46 Million | +45.19% |
| 2007-12-31 | $4.45 Million | +64.64% |
| 2006-12-31 | $2.70 Million | +3607.66% |
| 2005-12-31 | $72.93K | +3.48% |
| 2004-12-31 | $70.47K | -10.59% |
| 2003-12-31 | $78.82K | -0.32% |
| 2002-12-31 | $79.07K | +2.33% |
| 2001-12-31 | $77.28K | -86.22% |
| 2000-12-31 | $560.61K | +22.04% |
| 1999-12-31 | $459.36K | -67.61% |
| 1998-12-31 | $1.42 Million | -81.01% |
| 1997-12-31 | $7.47 Million | +1.73% |
| 1996-12-31 | $7.34 Million | -- |
About Protalix Biotherapeutics Inc
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also d… Read more